Prabotulinumtoxin A

Summary

Prabotulinumtoxin A (CHEMBL4297229) is an approved unknown; indicated across 3 conditions including migraine disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• Indications: 3 conditions
• Clinical trials: 16

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297229
Name	Prabotulinumtoxin A
Type	Unknown
Max phase	4

Also known as: ABP 450, ABP-450, ABP450, Botulinum toxin type a complex, DWP-450, DWP450, Evosyal, Jeuveau, Nabota, Prabotulinumtoxin a, Prabotulinumtoxina, Prabotulinumtoxina xvfs

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
migraine disorder	2	MONDO:0005277	MONDO:0005277

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 16.

Phase distribution

Phase	Trials
PHASE2	5
EARLY_PHASE1	3
Not specified	3
PHASE4	2
PHASE3	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06903975	PHASE4	RECRUITING	BoTox Into the Sternocleidomastoid Muscles (SCM)
NCT05840445	PHASE4	COMPLETED	Efficacy of Prabotulinum and Onabotulinum Toxin-A for Facial Wrinkles
NCT04294251	PHASE3	COMPLETED	Efficacy and Safety of DWP450 in Subjects With Benign Masseteric Hypertrophy
NCT06354127	PHASE3	COMPLETED	DWP450 for Treating Moderate to Severe Glabellar Lines
NCT04845178	PHASE2	COMPLETED	Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults
NCT04849988	PHASE2	COMPLETED	A Phase 2 Study to Evaluate the Safety and Efficacy of ABP-450 in the Treatment of Cervical Dystonia
NCT04871451	PHASE2	COMPLETED	Extension Study of ABP-19000 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 in Cervical Dystonia
NCT05016661	PHASE2	TERMINATED	Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine Prevention
NCT05320393	PHASE2	COMPLETED	Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines
NCT06604832	PHASE1	COMPLETED	Effects of Microtox on Facial Skin Quality, Fine Wrinkles, and Texture
NCT04715048	EARLY_PHASE1	UNKNOWN	Split-Face Study Comparing Botox and Jeuveau in Treating Glabellar Lines
NCT05129319	EARLY_PHASE1	COMPLETED	Jeuveau Treatment of Glabellar Lines Using OLD Versus COLD
NCT05807412	EARLY_PHASE1	COMPLETED	Spread of PrabotulinumtoxinA-xvfs Versus OnabotulinumtoxinA in the Treatment of Forehead Rhytides
NCT05167864	Not specified	COMPLETED	Evaluation of Four Injectable Neuromodulators in the Glabella Area Glabella Area
NCT05481931	Not specified	COMPLETED	Non Interventional Safety Study of NUCEIVA for the Treatment of Moderate-to-Severe Glabellar Lines
NCT07452510	Not specified	COMPLETED	Comparison of Dry Needling and Two Botulinum Toxins for Bruxism

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).